A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Trial Details

NCT ID
NCT07409428
Phase
PHASE3
Sponsor
Hutchmed
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • HMPL-760
  • HMPL-760 Placebo
  • R-GemOx
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Baoding, China|38.87288,115.46246
  • Beijing, China|39.9075,116.39723
  • Bengbu, China|32.94083,117.36083
  • Changchun, China|43.88,125.32278

Key Eligibility Criteria

  • Sign the ICF and be able to follow the requirements of study protocol;
  • Age ≥18 years;
  • ECOG performance status score between 0 and 2;
  • Histopathologically confirmed diagnosis of DLBCL;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →